Pulmonary Sarcoidosis Clinical Trial
Official title:
A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS
Verified date | December 2019 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
Status | Terminated |
Enrollment | 1 |
Est. completion date | September 23, 2013 |
Est. primary completion date | September 23, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of biopsy-proved chronic pulmonary sarcoidosis either Stage 2 or Stage 3 for at least 1 year; - Forced Vital Capacity (FVC) lung assessment of >40% and < or = to 80% predicted normal values at screening; - age 21-75 years of age; - treatment with a stable (longer than 4 weeks) regimen of corticosteroids (between 10 and 30 mg of prednisone) for at least 3 months prior to Screening; (other anti-inflammatory drugs may be permitted as defined by the study protocol) Exclusion Criteria: - History of any other pulmonary (lung) disease than sarcoidosis (ex, asthma requiring maintenance treatment, chronic obstructive pulmonary disease (COPD)); - Pulmonary hypertension, significant lung fibrosis, any chronic infection (eg, TB, HIV); - treatment with other biologic anti-inflammatory/immuno-modulatory drugs; - active smokers; - class 3 or 4 congestive heart failure; - cancer, or history of cancer within past 5 years; - history of ischemic heart disease, heart attack, stroke, any heart muscle disease; - liver disease; - history of alcohol or drug abuse |
Country | Name | City | State |
---|---|---|---|
United States | Iinterstitial Lung Disease & Sarcoidosis Clinic | Cincinnati | Ohio |
United States | Medical Arts Building | Cincinnati | Ohio |
United States | The Barrett Cancer Center at UC Health | Cincinnati | Ohio |
United States | University Hospital | Cincinnati | Ohio |
United States | Mount Sinai School Of Medicine/Mount Sinai Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline (Absolute) in % Predicted Forced Vital Capacity (FVC) Compared to Placebo at Week 16 | The percent predicted FVC was calculated by observed FVC/predicted FVC * 100. The predicted FVC values was calculated according to age, height, race and gender. FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. | Baseline, Week 16 | |
Secondary | Change From Baseline in Chest X-ray Global Assessment Score (5-point ) | Digital copies of Chest x-rays performed during the study were graded according to a 5 point Likert scale: 1 = markedly worsened; 2 = worsened; 3 = unchanged; 4 = improved; and 5 = markedly improved. Baseline will be defined as the last available x-ray prior to first dose. | Baseline, Week 16 | |
Secondary | Change From Baseline in FVC (Absolute ) Compared to Placebo at Weeks 2,4,8,12, 14, and 20 | FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was obtained from spirometry, performed before study treatment administration. | Baseline, Weeks 2, 4, 8, 12, 14, and 20 | |
Secondary | Change From Baseline Absolute in FVC (% Predicted) Compared to Placebo at Weeks 2,4,8,12,14, and 20 | The percent predicted FVC was calculated by observed FVC/predicted FVC * 100. The predicted FVC values was calculated according to age, height, race and gender. FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. | Baseline, Weeks 2, 4, 8, 12, 14, and 20 | |
Secondary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 2,4,8,12,14, 16 and 20 | FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Trough FEV1 was obtained from spirometry, performed before study treatment administration. | Baseline, Weeks 2, 4, 8, 12, 14, 16, and 20 | |
Secondary | Change From Baseline in % Predicted FEV1 at Weeks 2,4,8,12,14, 16 and 20 | The percent predicted FEV1 was calculated by observed FEV1/predicted FEV1 * 100. The predicted FEV1 values was calculated according to age, height, race and gender. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. | Baseline, Weeks 2, 4, 8, 12, 14, 16, and 20 | |
Secondary | Change From Baseline in Ratio of FEV1/FVC at Weeks 2,4,8,12,14, 16 and 20 | FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Trough FEV1 was obtained from spirometry, performed before study treatment administration. FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was obtained from spirometry, performed before study treatment administration. | Baseline, Weeks 2, 4, 8, 12, 14, 16, and 20 | |
Secondary | Estimated Treatment Effect Over Placebo in FVC Averaged Over 16 Weeks | FVC is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Through FVC was obtained from spirometry, performed before study treatment administration. | Baseline, Weeks 0, 2, 4, 8, 12, 14, 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04064242 -
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Terminated |
NCT00262132 -
Mycophenolate for Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT05415137 -
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT04318392 -
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Completed |
NCT01587001 -
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05890729 -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02824419 -
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06205121 -
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
|
Phase 2 | |
Completed |
NCT02200146 -
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
|
Phase 3 | |
Enrolling by invitation |
NCT06169397 -
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 2 | |
Active, not recruiting |
NCT05368883 -
Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
|
N/A | |
Not yet recruiting |
NCT05247554 -
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
|
Phase 3 | |
Completed |
NCT03599414 -
CASPA: CArdiac Sarcoidosis in PApworth
|
||
Recruiting |
NCT02188017 -
Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
|
Phase 4 | |
Recruiting |
NCT06113991 -
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
|
||
Completed |
NCT01169038 -
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
|
Phase 1 | |
Completed |
NCT00701207 -
Study of Nicotine Patches in Patients With Sarcoidosis
|
Early Phase 1 | |
Completed |
NCT03824392 -
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
|
Phase 1/Phase 2 |